Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors
Deciphera Pharmaceuticals, LLC
Deciphera Pharmaceuticals, LLC
Novartis
National Cancer Institute (NCI)
Turning Point Therapeutics, Inc.
OHSU Knight Cancer Institute